A new study co-led by the University of Warwick Clinical Trials Unit has shown that shortening the duration of a therapy for breast cancer patients does not increase the risk of their cancer returning ...

Two recent studies offer hope of enhancing both the effectiveness and safety of Herceptin, the drug that helped introduce the era of targeted therapy. Two studies presented Saturday offer hope of ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the U.S. Food and Drug Administration (FDA) has approved Herceptin ® ...

Keytruda plus the combination of Herceptin and chemotherapy led to an improvement in progression-free survival versus placebo plus Herceptin and chemotherapy in the first-line treatment of some ...

For women with HER2 positive early-stage breast cancer taking Herceptin for six months could be as effective as 12 months in preventing relapse and death, and can reduce side effects, finds new ...

The approval of Ogivri was based on data demonstrating that the biosimilar product is highly similar to the reference product, Herceptin. In addition, long-term data from the HERITAGE study, which ...

Sometimes less may be better when it comes to treatment for breast cancer. A new study finds that women who have been diagnosed with early-stage HER2-positive breast cancer did just as well with six ...

BRUSSELS - The targeted drug trastuzumab, or Herceptin, previously shown to prolong survival in advanced breast cancer, dramatically reduced the chances of recurrence in patients with early-stage ...